The treatment of hirsutism in polycystic ovary syndrome

Ethical implications of ‘saviour siblings’
August 6, 2021
Contribution of ion channel mutations to neuro-degeneration
August 6, 2021

The treatment of hirsutism in polycystic ovary syndrome

Example human biology dissertation topic 2:

The treatment of hirsutism in polycystic ovary syndrome

While hirsutism does not pose any specific health dangers the effect of living with the affliction on women can result in psychological issues. With one in fifteen women worldwide being affected by polycystic ovary syndrome, there is a real need for an effective method of treatment. Use of spironolactone has been found to provide only limited effects on hair growth while also being avoided by many doctors due to its weight gain side effects. The relatively new use of a topical cream, Vaniqa, has also proven to be controversial as it can only effect results while being used. Therefore, this dissertation will focus on further possible pharmacological treatments of hirsutism in PCOS and factors which reduce the effectiveness of the treatment.

Suggested initial topic reading:

  • Escobar-Morreale, H., Carmina, E., Dewailly, D., Gamineri, A., Kelestimur, F., Moghetti, P., Pugeat, M., Qiao, J., Wijeyratne, C.N., Witchel, S.F. and Norman, A.J. (2011) ‘Epidemiology, diagnosis and management of hirsutism: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society‘, Human Reproductive Update, Vol. 18(2), pp. 146-170.
  • Harborne, L., Fleming, R., Lyall, H., Sattar, N. and Norman, J. (2003) ‘Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome’, Journal of Clinical Endocrinology and Metabolism, Vol.88(9), pp. 4116-4123.
  • Moghetti, P. and Toscano, V. (2006) ‘Treatment of hirsutism and acne in hyperandrogenism’, Best Practice & Research Clinical Endocrinology & Metabolism, Vol. 20(2), pp. 221-234.
  • Witchel, S. (2006) Pediatric endocrinologyVolume 2. New York: Informa Healthcare USA.